Phathom presents new VOQUEZNA analyses in GERD at ACG 2026 meeting
PHAT•Phathom Pharmaceuticals said it will present new analyses of VOQUEZNA in GERD at the ACG 2026 meeting in Nashville. Posters are scheduled for Oct. 11-13, with a product theater on Oct. 12.
1. Analyses scheduled
The planned analyses examine real-world patient profiles, symptom relief across weight groups, and an economic model comparing VOQUEZNA with proton pump inhibitors in erosive disease. The results have not yet been presented.
